Deferoxamine Mesylate (Deferoxamine Mesylate) Patent Expiration, LOE Window & CMS Spending

Deferoxamine Mesylate (Deferoxamine Mesylate) by Multi-Source Generic Manufacturers: Multi-Source Generic Molecule, 4 AB generics, $1.4M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMulti-Source Generic Manufacturers
FDA Application & PathwayReconciled (ANDA)
Exclusivity / Cliff HorizonMulti-Source Generic Molecule
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors4
2024 CMS Total Public Spend$1.4M
2024 Medicare Part D Spend$108K
2024 Medicaid Spend$1.3M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 27.1% 2-yr change)